ASCO GUIDELINES Bundle

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475447

Contents of this Issue

Navigation

Page 12 of 13

13 Table 2. Classification of Patients According to Clinical Risk Assessment by the Modified Version of Adjuvant!Online as Reported by Cardoso et al, 2016 ER status HER2 status Grade Nodal status Tumor size Clinical Riskin MINDA CT ER negative HER2 negative Well differentiated N– ≤2 cm C-low 2.1–5 cm C-high 1–3 positive nodes Any size C-high Moderately differentiated OR poorly differentiated or undifferentiated N– ≤1 cm C-low 1.1–5 cm C-high 1–3 positive nodes Any size C-high HER2 positive Well differentiated OR moderately differentiated N– ≤1 cm C-low 1.1–5 cm C-high 1–3 positive nodes Any size C-high Poorly differentiated or undifferentiated Any Any size C-high (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer